Polyethylene glycol (PEG) is a polymer that is attached to peptides, proteins, nucleic acids, liposomes and nanoparticles to create effective medicines. However, immune responses to PEG can adversely impact drug efficacy and safety. Dr. Steve R. Roffler at the Institute of Biomedical Sciences provide a framework to understand PEG immunogenicity and how antibodies against PEG affect pegylated medicines. The widespread use of SARS-CoV-2 RNA vaccines that incorporate PEG in lipid nanoparticles make understanding effects of anti-PEG antibodies on pegylated medicines even more critical.

Article Link: https://pubs.acs.org/doi/abs/10.1021/acsnano.1c05922